4th How to Diagnose and Treat:
Lymphoma
November 1-3, 2024 - Stockholm, Sweden
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont

Friday, November 1, 2024

08:35-08:45 Welcome: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont

SESSION I – Aggressive B cell lymphomas: Diffuse large B cell lymphoma, High grade B cell lymphoma and Burkitt
Chair: Martine Chamuleau (Amsterdam)

08:45-09:05	Case-based lecture: Incorporation of novel agents into frontline therapy for diffuse large B cell lymphoma: Have we made progress/improved outcomes?	Marie José Kersten (Amsterdam)
09:05-09:10	*Discussion*	
09:10-09:25	Interactive case: Treatment of mediastinal large B cell lymphoma: what is the standard	Andrew Davies (Southampton)
09:25-09:30	*Discussion*	
09:30-09:50	Case-based lecture: Approach to double hit lymphomas: Is there an optimal front-line approach?	Jeremy Abramson (Boston)
09:50-09:55	*Discussion*	
09:55-10:15	Case-based lecture: What is the optimal treatment for Burkitt lymphoma in adults?	Martine Chamuleau (Amsterdam)
10:15-10:20	*Discussion*	
10:20-10:25	*Brief oral communication* *The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review*	*Maifa Belghoul (Chichester)*
10:25-10:28	*Discussion*	
10:28-10:50	*Panel discussion*	

10:50-11:20 Coffee Break

SESSION II – Mantle cell lymphoma
Chair: Mats Jerkeman (Lund)

11:20-11:35	Interactive case: Should all patients initiate treatment after diagnosis?	Sylvain Carras (Grenoble)
11:35-11:40	*Discussion*	
11:40-12:00	Case-based lecture: Optimal treatment for younger patients	Martin Dreyling (Munich)
12:00-12:05	*Discussion*	

12:05-12:25 Case-based lecture: Optimal treatment of older patients — Mats Jerkeman (Lund)
12:25-12:30 *Discussion*

12:30-12:50 Case-based lecture: Relapsed and refractory: Novel agents including bispecifics, BTKIs and other agents — Morgane Cheminant (Paris)
12:50-12:55 *Discussion*

12:55-13:00 *Briel oral communication* — *Martin Dreyling (Munich)*
Acalabrutinib plus Bendamustine and Rituximab in Untreated Mantle Cell Lymphoma: Results From the Phase 3, Double-blind, Placebo-controlled ECHO Trial
13:00-13:03 *Discussion*

13:03-13:25 *Panel discussion*

13:25-15:20 Lunch

14:10-15:10 SATELLITE SYMPOSIUM:
Redefining fitness and first-line treatment selection in chronic lymphocytic leukaemia (CLL)
Chair: Raúl Córdoba Mascuñano (Madrid)
Speakers: Lydia Scarfò (Milan), Martin Trepel (Augsburg)

This symposium is organised and supported by J&J Innovative Medicine

SESSION III – Challenging T-cell lymphomas
Chair: Anca Prica (Toronto)

15:20-15:35 Interactive case: Follicular T helper cell lymphomas: Biology and therapy — François Lemonnier (Paris)
15:35-15:40 *Discussion*

15:40-16:00 Case-based Lecture: The challenge of relapsed T cell lymphoma — Kerry Savage (Vancouver)
16:00-16:05 *Discussion*

16:05-16:25 Case-based Lecture: Rare T-cell lymphoma — Giuseppe Gritti (Bergamo)
16:25-16:30 *Discussion*

16:30-16:50 Case-based lecture: Cutaneous T-cell lymphoma: when to consider systemic therapy and what are the best options in first and second line — Steven Horwitz (New York)
16:50-16:55 *Discussion*

16:55-17:25 *Panel discussion*

17:25-17:55 Coffee break

17:55-18:35 DEBATE 1 – Mantle Cell lymphoma: Optimal cellular therapy for relapsed disease CAR-T vs AlloSCT
Chair: Martin Dreyling (Munich)

Audience votes

17:55-18:10 Allogeneic stem cell transplantation is the only curative option for relapsed Mantle Cell lymphoma — Stephan Mielke (Stockholm)

18:10-18:25 CAR-T cell therapy is the preferred cellular therapy for patients — Marie José Kersten (Amsterdam)

with relapsed Mantle Cell lymphoma

18:25-18:35 *Discussion*

Audience votes again

18:35-19:15 ROUNDTABLE 1 – Diffuse large B cell lymphoma
Chair: Gilles Salles (New York)

18:35-18:50	Optimizing treatment outcomes using biomarker-driven approaches	Sirpa Leppä (Helsinki)
18:50-19:05	Primary CNS lymphoma: When to use an intensive therapy approach	Anca Prica (Toronto)
19:05-19:15	*Discussion*	

19:15 – 20:15 ***Poster Walks and Welcome Get Together stand-up buffet dinner***
Poster Walk 1 Leaders: Mats Jerkeman (Lund), Kerry Savage (Vancouver)
Poster Walk 2 Leaders: Martin Dreyling (Munich), Sirpa Leppä (Helsinki)

Saturday, November 2, 2024

07:45-08:45 3 Simultaneous Meet the Expert sessions

1. Management of relapsed Mantle Cell lymphoma	Mats Jerkeman (Lund)
2. Bispecific antibodies in B-cell lymphoma: Managing adverse events	Kim Linton (Manchester)
3. Can prognostic factors help treatment decisions in patients with Follicular lymphoma?	Jessica Okosun (London)

08:50-09:50 SATELLITE SYMPOSIUM:
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
Chair: Gilles Salles (New York)
Speakers: Paul Bröckelmann (Cologne), Ann S. LaCasce (Boston)

This independent educational activity is supported by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

09:50-10:20 Coffee Break and Poster viewing

SESSION IV – Diffuse large B-cell lymphoma: Immune based therapy
Chair: Kim Linton (Manchester)

10:20-10:35	Interactive case: Patient selection for CAR-T cell therapy for diffuse large B cell lymphoma	Andrea Kuhnl (London)
10:35-10:40	*Discussion*	
10:40-11:00	Case-based lecture: CD19 CAR-T cell therapy for relapsed/refractory diffuse large B cell lymphoma: Patient selection and treatment approach	Kai Rejeski (New York)
11:00-11:05	*Discussion*	
11:05-11:25	Case-based lecture: Beyond CD19-directed CAR-T Cell therapy:	Margot Jak (Utrecht)

Current results
11:25-11:30 *Discussion*

11:30-11:50 Case-based lecture: Bispecific in 2024: how and when — Kim Linton (Manchester)
11:50-11:55 *Discussion*

11:55-12:00 *Brief oral communication* — *Jeremy S. Abramson (Boston)*
Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from the global randomised Phase III STARGLO trial

12:00-12:03 Discussion

12:03-12:25 Panel

12:25-14:20 Lunch

13:10-14:10 SATELLITE SYMPOSIUM:
Comprehensive insights into MCL management: exploring therapeutic innovations and addressing unmet needs for relapsed / refractory patients
Chair: Mats Jerkeman (Lund)
Speakers: Maria Gomes da Silva (Lisbon), Georg Hess (Mainz)

This educational symposium is organized and funded by Lilly

14:20-15:30 ROUNDTABLE 2 – Novelties in marginal zone lymphoma and Waldenström macroglobulinemia
Chairs: Christian Buske (Ulm), Catherine Thieblemont (Paris)

14:20-14:35 The many faces of Splenic and nodal marginal zone lymphoma — Francesco Bertoni (Bellinzona)

14:35-14:50 High-risk marginal zone lymphoma — Luca Arcaini (Pavia)

14:50-15:05 New era in marginal zone lymphomas: IBTK new generation, bispecifics, CAR-T — Catherine Thieblemont (Paris)

15:05-15:20 Update on Waldenström Macroglobulinemia — Christian Buske (Ulm)

15:20 – 15:30 *Discussion*

15:30-16:10 DEBATE 2 –-What is the optimal regimen for advanced Hodgkin's lymphoma?
Chair: Michael Crump (Toronto)

Audience votes

15:30-15:45 Checkpoint inhibitors should be standard for frontline therapy — Ann LaCasce (Boston)

15:45-16:00 PET-adapted intensified chemotherapy is the optimal 1st-line treatment of advanced-stage Hodgkin's lymphoma — Paul J Bröckelmann (Cologne)
16:00-16:10 *Discussion*

Audience votes again

16:10-16:40 Coffee break and Poster Viewing

SESSION V- Chronic lymphocytic leukemia
Chair: Othman Al-Sawaf (Cologne)

16:40-17:00	Case-based lecture: Primary therapy: finite vs continuous and how to chose	Othman Al-Sawaf (Cologne)
17:00-17:05	*Discussion*	
17:05-17:25	Case-based lecture: optimizing treatment of relapse in the era of upfront BTKI	Francesc Bosch (Barcelona)
17:25-17:30	*Discussion*	
17:30-17:50	Case-based lecture: Richter's transformation	Barbara Eichhorst (Cologne)
17:50-17:55	*Discussion*	
17:55-18:00	*Brief oral communication*	*Lea Ryffel (Mulhouse)*
	MYD88 L265P on circulating tumor DNA for Waldenström diagnosis	
18:00-18:03	*Discussion*	
18:03-18:25	*Panel discussion*	

Sunday, November 3, 2024

08:15-09:15 3 Simultaneous Meet the Expert Sessions

1. Managing patients with diffuse large B cell lymphoma relapsing after CAR-T cell therapy	Marie José Kersten (Amsterdam)& Catherine Thieblemont (Paris)
2. The role of MRD in Hodgkin lymphoma	Christian Steidl (Vancouver)
3. Practicalities of Immune-Checkpoint Inhibition in Hodgkin Lymphoma	Paul J. Bröckelmann (Cologne)

SESSION VI – Follicular Lymphoma
Chair: Christian Buske (Ulm)

09:15-09:35	Case-based lecture: Firstline Therapy	Jessica Okosun (London)
09:35-09:40	*Discussion*	
09:40-10:00	Case-based lecture: Relapse	Gilles Salles (New York)
10:00-10:05	*Discussion*	
10:05- 10:12	*Brief oral communication*	*Kristina Drott (Lund)*
	Epcoritamab combined with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance therapy in FL: Results from EPCORE NHL-2 arms 6 and 7	
10:12-10:15	*Discussion*	
10:15-10:45	*Panel discussion*	

10:45-11:15 ***Coffee Break and Poster viewing***

11:15-11:55 DEBATE 3 –-Follicular Lymphoma: Bispecific VS CAR-T
Chair: Michael Crump (Toronto)

Audience votes

11:15-11:30	Bispecifics	Kim Linton (Manchester)

11:30-11:45	CAR-T cells	Emmanuel Bachy (Lyon)
11:45-11:55	*Discussion*	

Audience votes again

11:55-12:25 Keynote lecture
Chair: Paul J Bröckelmann (Cologne)

11:55-12:15	Immune environment in Hodgkin's lymphoma: time to chart the new frontier	Christian Steidl (Vancouver)
12:15-12:25	Discussion	

12:25-12:30 Closing remarks

MEETING CLOSURE